Skip to main content

Aerobic Exercise Tied to Improved Clinical Asthma Outcomes

Medically reviewed by Carmen Pope, BPharm. Last updated on June 24, 2024.

By Lori Solomon HealthDay Reporter

MONDAY, June 24, 2024 -- Moderate- and vigorous-intensity aerobic exercise training are associated with improvements in clinical asthma outcomes, according to a study published online June 9 in the Journal of Allergy and Clinical Immunology: in Practice.

Sarah R. Valkenborghs, Ph.D., from the University of Newcastle in Callaghan, Australia, and colleagues compared the effects of moderate- and vigorous-intensity aerobic exercise training on asthma outcomes and inflammation in 41 adults randomly assigned to 45 minutes moderate-intensity exercise training three times/week, 30 minutes of vigorous-intensity three times/week, or control.

The researchers found that compared to the control group, the moderate-intensity group had a statistically and clinically significant improvement in asthma-related quality of life (AQLQ) and asthma control. The vigorous-intensity group had statistically, but not clinically, significant improvement in AQLQ and asthma control, compared to the control group. There was a reduction in sputum macrophage and lymphocyte counts observed following moderate-intensity training, compared to control. A reduction in android fat mass was associated with improved AQLQ and reduced sputum interleukin-6; however, no association was seen with change in fitness.

"As both moderate- and vigorous-intensity exercise have benefit in adults with asthma, both can be recommended, which empowers people to exercise at their preferred intensity," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted June 2024

Read this next

Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million

TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...

Patient–Primary Care Provider Language Concordance Tied to Better Outcomes

TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...

Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care

TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.